European Biotech Acquisition Corp. (NASDAQ:EBAC – Get Rating) was the target of a large growth in short interest during the month of October. As of October 31st, there was short interest totalling 11,000 shares, a growth of 746.2% from the October 15th total of 1,300 shares. Approximately 0.1% of the company's shares are sold short. Based on an average trading volume of 21,100 shares, the days-to-cover ratio is presently 0.5 days.
Hedge Funds Weigh In On European Biotech Acquisition
Institutional investors have recently modified their holdings of the business. Cubist Systematic Strategies LLC lifted its stake in European Biotech Acquisition by 136.0% in the second quarter. Cubist Systematic Strategies LLC now owns 60,555 shares of the company's stock valued at $593,000 after buying an additional 34,896 shares in the last quarter. Calamos Advisors LLC acquired a new position in European Biotech Acquisition in the 3rd quarter worth $992,000. Finally, Periscope Capital Inc. increased its holdings in European Biotech Acquisition by 66.5% during the 3rd quarter. Periscope Capital Inc. now owns 843,223 shares of the company's stock worth $8,362,000 after purchasing an additional 336,744 shares in the last quarter.
Get European Biotech Acquisition alerts:European Biotech Acquisition Price Performance
Shares of NASDAQ:EBAC opened at $9.99 on Friday. The firm has a 50 day moving average price of $9.94. European Biotech Acquisition has a 52 week low of $9.66 and a 52 week high of $10.50.
European Biotech Acquisition Company Profile
(Get Rating)European Biotech Acquisition Corp. does not have significant operations. The company intends to effect a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses or entities. European Biotech Acquisition Corp. was incorporated in 2021 and is based in Amsterdam, the Netherlands.
Further Reading
- Get a free copy of the StockNews.com research report on European Biotech Acquisition (EBAC)
- MarketBeat: Week in Review 11/7 – 11/11
- Oil Is a Compelling Reason The Sell-Off In Stocks Isn't Over
- Is Mid-Cap Neurocrine Biosciences A Buy After Blowout Q3 Report?
- Six Flags is a Ride You Don't Want to Get Stuck On
- Hanesbrands May be Signaling a Bad Week for Retail Stocks
Receive News & Ratings for European Biotech Acquisition Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for European Biotech Acquisition and related companies with MarketBeat.com's FREE daily email newsletter.